Abcam, ab229413, Human GLP-1 (7-36) ELISA Kit, Fluorescent

Size: 1 x 96Tests
Human GLP-1 (7-36) ELISA Kit, Fluorescent is a single-wash 90-min Simplestep used to quantify Human GLP-1 (7-36) with a sensitivity of 12 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Fluorescent Sandwich ELISA - 530/570/590 nm readout : works on any standard plate reader
Key facts
Detection method:Fluorescent,
Sample types:Heparin Plasma, Citrate plasma, Cell culture supernatant, Serum,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 12 pg/mL,
Range:14.6 - 1000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
GLP-1 (7-36)
in vitro
CatchPoint SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of GLP-1 (7-36) protein in human serum, plasma, and cell culture supernatants.
This CatchPoint SimpleStep ELISA kit has been
optimized for Molecular Devices Microplate Readers
. Click
for a list of recommended Microplate Readers.
If using a Molecular Devices' plate reader supported by SoftMax® Pro software, a preconfigured protocol for these CatchPoint SimpleStep ELISA Kits is available with all the protocol and analysis settings at
www.softmaxpro.org
The CatchPoint SimpleStep ELISA employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. CatchPoint HRP Development Solution containing the Stoplight Red Substrate is added. During incubation, the substrate is catalyzed by HRP generating a fluorescent product. Signal is generated proportionally to the amount of bound analyte and the intensity is measured in a fluorescence plater reader at 530/570/590 nm Excitation/Cutoff/Emission.
GLP-1 (Glucagon like peptide 1) is part of the group of incretin hormones that are secreted by the gastrointestinal tract in response to food intake to assist glucose stimulated insulin secretion and glucagon suppression. GLP-1 is a 30 aminoacid peptide cleaved from proglucagon and released by the L-cells of the distal ileum. The intracellular precursor of GLP-1 (1-37) is cleaved to form the active peptides GLP-1 (7-37) and GLP-1 (7-36)NH
. The active peptides bind to the GLP-1 receptor (GLP-1r) expressed in the pancreatic beta cell and are quickly metabolized by the enzyme dipeptidyl peptidase IV (DPP-IV) to form the peptide GLP-1 (9-36), which has no insulin stimulating activity. Binding of active GLP-1 to the receptor, increases cAMP levels and potentiates insulin secretion via Protein Kinase A (PKA) and the cAMP-regulated nucleotide exchange factor (Epac2). GLP-1 and its receptor are also suggested to play a role in the central nervous systems as mediators of satiety. Intracerebroventricular GLP-1 has been shown to induce c-FOS activity in the hypothalamus and the central nucleus of the amygdala, both of which are important in the regulation of appetite.
The role of GLP-1 in chronic diseases is controversial. Patients with type-II diabetes as well as morbidly obese subjects have been shown to have lower secretion of post-prandial GLP-1, which improves with treatment or weight loss. Due to the beneficial effects of active GLP-1 as well as GLP-1r agonists in metabolic diseases, GLP-1 has been proposed to be an effective therapeutic approach to lowering glycemic levels and decreasing body fat content. Furthermore, GLP-1 has been found to be cardioprotective during acute myocardial infarction. In contrast with the GLP-1 protective findings, circulating GLP-1 has also been found to positively correlate with serum triclycerides and high levels are significantly associated with coronary plaque burden in patients receiving coronary CT-angiography.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GLP-1 also known as glucagon-like peptide-1 is a 30 or 31 amino acid peptide with a mass of approximately 3.3 kDa. This peptide is mainly secreted by intestinal L-cells and the CNS. It enhances the secretion of insulin in response to glucose making it an important regulator of blood sugar levels. GLP-1 is degraded by dipeptidyl peptidase-4 which rapidly reduces its activity. Researchers often target GLP-1 in studies aimed at understanding metabolic processes and developing therapeutic interventions.
Biological function summary
GLP-1 influences several physiological functions by acting on its receptor GLP-1R a G-protein coupled receptor. It is not part of a complex but exerts its effects through binding to this receptor. Activation of GLP-1R promotes insulin secretion suppresses glucagon release slows gastric emptying and promotes satiety. This makes GLP-1 an important regulator in energy homeostasis and nutrient absorption. Its effects on appetite and food intake are of particular interest in obesity research.
Pathways
GLP-1 is an essential component of the incretin pathway which regulates insulin secretion in response to food intake. The interaction between GLP-1 and the GLP-1 receptor activates the adenylate cyclase pathway leading to increased cAMP and PKA signaling in pancreatic beta-cells. This chain of events enhances the insulin-secreting ability of these cells. Furthermore GLP-1 has connections with proteins such as insulin and glucagon through its regulatory functions in glucose metabolism.
GLP-1 is highly relevant to type 2 diabetes and obesity. Its ability to enhance insulin secretion and promote weight loss has made it a target for drug development in the treatment of these conditions. Antidiabetic medications including GLP-1 receptor agonists exploit this mechanism to control blood sugar levels effectively. Additionally GLP-1's connection to insulin makes it a significant focus in diabetes research as imbalances in these proteins contribute to the disease pathology.